Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: Importance of the N-[2(dimethylamino)ethyl]carbamoyl side chain

Molecular Pharmacology

Volumn 58, Issue 4, 2000, Pages 709-718

  Le Mée, Sandrine ^a   Chaminade, Françoise ^a   Delaporte, Charlotte ^a   Markovits, Judith ^a   Saucier, Jean Marie ^a   Jacquemin Sablon, Alain ^a,b  

^a CNRS   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GYRASE INHIBITOR; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CHINESE HAMSTER; CONTROLLED STUDY; CROSS RESISTANCE; DNA SEQUENCE; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; FIBROBLAST; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

EID: 0033798791     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.58.4.709     Document Type: Article

References (38)

1. Multimodal action of antitumor agents on DNA: The ellipticine series
2. Physicochemical and pharmacological properties of the antitumor ellipticine derivative 2-(diethylamino-2-ethyl)9-hydroxyellipticinium-chloride, HCl
3. Structure and mechanism of DNA topoisomerase II
4. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
5. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line
6. Effects of 9-OH-ellipticine on cell survival, macromolecular synthesis, and cell cycle progression in sensitive and resistant Chinese hamster lung cells
7. Uptake and cytofluorescence localization of ellipticine derivatives in sensitive and resistant Chinese hamster lung cells
8. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease
9. Effects of verapamil on the cellular accumulations and cytotoxicity of several antitumor drugs in 9-hydroxy-ellipticine-resistant cells
10. Influence of myc overexpression on the phenotypic properties of Chinese hamster lung cells resistant to antitumor agents
11. Role of topoisomerase IIβ in the resistance of 9-OH-allipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors
12. Cloning and characterization of full-length cDNAs coding for the DNA topoisomerase IIβ from Chinese hamster lung cells sensitive and resistant to 9-OH-ellipticine
13. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
14. Antitumor activity of S16020-2 in two orthotopic models of lung cancer
15. In vivo antitumor activity of S16020-2, a new olivacine derivative
16. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 2. Kinetic mechanism for the sequential hydrolysis of two ATP
17. Pre-steady-state analysis of ATP hydrolysis by Saccharomyces cerevisiae DNA topoisomerase II. 1. A DNA-dependent burst in ATP hydrolysis
18. Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II α
19. Synthesis and evaluation of 9-hydroxy-5-methyl (and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole 1-N(dialkylaminoalkyl) substituted carboxamides, a new promising series of antitumor olivacine derivatives
20. Expression of topoisomerase IIα and β in Chinese hamster lung cells resistant to topoisomerase II inhibitors
21. Expression of human topoisomerase IIα in 9-OH-ellipticine resistant Chinese hamster fibroblasts: Variable effects on the cell sensitivity to different topoisomerase II inhibitors
22. Measurement of DNA strand breaks and cross-links by alkaline elution
23. Point mutations of the topoisomerase IIα gene in patients with small cell lung cancer treated with etoposide
24. Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxyellipticine
25. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition
26. A new antitumoral agent: 9-hydroxyellipticine: Possibility of a rational design of anticancerous drugs in the series of DNA intercalating drugs
27. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
28. DNA topoisomerase poisons as antitumor drugs
29. Antitumor activity, pharmacology, and toxicology of ellipticines, ellipticinium, and 9-hydroxy derivatives: Preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264 137)
30. Novel olivacine and ellipticine derivatives: S16020-2 and related compounds as potential antitumor agents
31. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: Kinetics of uptake and efflux in sensitive and resistant cell lines
32. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors
33. Expression of drug sensitivity and tumorigenicity in intraspecies hybrids between 9-hydroxyellipticine-sensitive and -resistant cells
34. Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives
35. Phase 2 study of elliptinium acetate salvage treatment of advanced breast cancer
36. Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives
37. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine
38. Nalidixic acid-resistant mutations of the gyr B gene of Escherichia coli